Next Article in Journal
Complex Virus–Host Interactions Involved in the Regulation of Classical Swine Fever Virus Replication: A Minireview
Next Article in Special Issue
Applicability of Metal Nanoparticles in the Detection and Monitoring of Hepatitis B Virus Infection
Previous Article in Journal
2BC Non-Structural Protein of Enterovirus A71 Interacts with SNARE Proteins to Trigger Autolysosome Formation
Previous Article in Special Issue
The Role of cccDNA in HBV Maintenance
Article Menu
Issue 7 (July) cover image

Export Article

Open AccessFeature PaperReview
Viruses 2017, 9(7), 172; doi:10.3390/v9070172

Hepatitis Delta Virus: Replication Strategy and Upcoming Therapeutic Options for a Neglected Human Pathogen

1
Department of Infectious Diseases, Molecular Virology, Heidelberg University, Im Neuenheimer Feld 345, 69120 Heidelberg, Germany
2
German Centre for Infection Research (DZIF), Partner Site Heidelberg, 69120 Heidelberg, Germany
*
Author to whom correspondence should be addressed.
Academic Editors: Ulrike Protzer and Michael Nassal
Received: 12 June 2017 / Revised: 28 June 2017 / Accepted: 29 June 2017 / Published: 4 July 2017
(This article belongs to the Special Issue Recent Advances in Hepatitis B Virus Research)
View Full-Text   |   Download PDF [1460 KB, uploaded 6 July 2017]   |  

Abstract

The human Hepatitis Delta Virus (HDV) is unique among all viral pathogens. Encoding only one protein (Hepatitis Delta Antigen; HDAg) within its viroid-like self-complementary RNA, HDV constitutes the smallest known virus in the animal kingdom. To disseminate in its host, HDV depends on a helper virus, the human Hepatitis B virus (HBV), which provides the envelope proteins required for HDV assembly. HDV affects an estimated 15–20 million out of the 240 million chronic HBV-carriers and disperses unequally in disparate geographical regions of the world. The disease it causes (chronic Hepatitis D) presents as the most severe form of viral hepatitis, leading to accelerated progression of liver dysfunction including cirrhosis and hepatocellular carcinoma and a high mortality rate. The lack of approved drugs interfering with specific steps of HDV replication poses a high burden for gaining insights into the molecular biology of the virus and, consequently, the development of specific novel medications that resiliently control HDV replication or, in the best case, functionally cure HDV infection or HBV/HDV co-infection. This review summarizes our current knowledge of HBV molecular biology, presents an update on novel cell culture and animal models to study the virus and provides updates on the clinical development of the three developmental drugs Lonafarnib, REP2139-Ca and Myrcludex B. View Full-Text
Keywords: Hepatitis D virus; lonafarnib; REP2139-Ca; Myrcludex B; viroid Hepatitis D virus; lonafarnib; REP2139-Ca; Myrcludex B; viroid
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Lempp, F.A.; Urban, S. Hepatitis Delta Virus: Replication Strategy and Upcoming Therapeutic Options for a Neglected Human Pathogen. Viruses 2017, 9, 172.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top